Braxia Scientific Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Roger McIntyre

Geschäftsführender

CA$170.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	100.0%
Amtszeit als Geschäftsführer	4.5yrs
Eigentum des Geschäftsführers	5.2%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Roger McIntyre im Vergleich zu den Einnahmen von Braxia Scientific verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	n/a	n/a	-CA$10m
Sep 30 2023	n/a	n/a	-CA$11m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	CA$238k	CA$238k	-CA$13m
Dec 31 2022	n/a	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$13m
Jun 30 2022	n/a	n/a	-CA$12m
Mar 31 2022	CA$300k	CA$300k	-CA$12m
Dec 31 2021	n/a	n/a	-CA$8m
Sep 30 2021	n/a	n/a	-CA$7m
Jun 30 2021	n/a	n/a	-CA$7m
Mar 31 2021	CA$277k	CA$277k	-CA$88m
Mar 31 2020	CA$119k	CA$119k	-CA$3m

Vergütung im Vergleich zum Markt: RogerDie Gesamtvergütung ($USD122.17K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Canadian ($USD172.63K).

Entschädigung vs. Einkommen: RogerDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Roger McIntyre

4.5yrs

Amtszeit

CA$170,500

Vergütung

Dr. Roger S. McIntyre, MD., FRCPC., is Chief Executive Officer and Director of Braxia Scientific Corp. since May 11, 2020 and July 22, 2020 respectively and serves as its Chairman of the Board since Octobe...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Roger McIntyre	Chairman & CEO	4.3yrs	CA$170.50k	5.17% CA$ 73.2k
Peter Rizakos	CFO & Director	less than a year	CA$134.04k	keine Daten
Jerry Habuda	Independent Director	5.3yrs	keine Daten	keine Daten
Leann Taylor	Director	2.2yrs	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: BRAXDie Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).

Braxia Scientific Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Recent updates

Braxia Scientific Corp., Annual General Meeting, Oct 04, 2024

Third quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 3Q 2023)

Less than half of directors are independent

Braxia Scientific Corp. Announces CFO Changes

Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.058 loss per share (vs CA$0.069 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.015 loss in 3Q 2022)

Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding

Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 2Q 2022)

Braxia Scientific Corp. Appoints Leann Taylor to Board of Directors

Braxia Scientific Corp. Announces Court Approval of Class Action Settlement in Canada

Braxia Scientific Corp. Announces It Has Successfully Launched KetaMD in Florida

Braxia Scientific Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Braxia Scientific Corp., Annual General Meeting, Oct 31, 2022

Braxia Scientific Corp. (CNSX:BRAX) acquired 100% stake in KetaMD, Inc.

Full year 2022 earnings released: CA$0.069 loss per share (vs CA$0.56 loss in FY 2021)

Braxia Scientific Corp. Appoints Jason Wolkove as Chief Information Officer

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Braxia Scientific Corp. Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Certification and Hearing to Approve Proposed Settlement of Braxia Scientific Corp. Securities Class Action

High number of new and inexperienced directors

Braxia Scientific Corp. Announces Resignation of David Greenberg as Director

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Corp. Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

Braxia Scientific Corp. announced that it has received CAD 3 million in funding

Braxia Scientific Corp. announced that it expects to receive CAD 3 million in funding

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Braxia Scientific Comments on US Class Action

Braxia Scientific Corp. Launches Psilocybin-Assisted Clinical Therapy Training Program to Develop New Generation of Qualified Physicians, Psychotherapists and Psychologists for Mental Health

Braxia Scientific Corp. Receives Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression

Zhang Investor Law Announces Class Action Lawsuit on Behalf of Shareholders Who Bought Shares of Champignon Brands Inc